ΒΆ microbiome
ΒΆ Definition
The collective genome and metabolic capacity of all microorganisms (bacteria, archaea, fungi, viruses, protozoa) living in and on the human body, primarily concentrated in the gastrointestinal tract. Represents a distributed metabolic organ containing approximately 100 trillion organisms from over 1000 species, with a gene count exceeding the human genome by 100-150 fold. Functions as an interface between host genetics, environmental exposures, and physiological state.
ΒΆ Picture It
Imagine your gut as a massive factory district spanning the length of a river valley. The river (your digestive tract) flows through different industrial zones, each specializing in different products. In the upper reaches (small intestine), you have fast-moving, oxygen-tolerant operations processing simple sugars. Downstream in the colon, the massive fermentation plants operate in oxygen-free environments, breaking down complex fibers that your own cellular machinery cannot touch.
These aren't passive factories β they're more like independent city-states that happen to live in your territory. They pay rent (producing vitamins, training your immune border guards, maintaining the factory walls), but they also influence policy decisions. Some bacterial residents send chemical signals that change your appetite, mood, and even whether your immune system treats newcomers as allies or invaders. When the factory district is diverse and balanced, the whole region thrives. But when one industrial sector takes over (dysbiosis), waste products accumulate, walls deteriorate, and the immune patrols start overreacting to everything. The factory fire alarms (inflammatory signals) won't stop ringing, and productivity across your entire metabolic economy collapses.
This is why antibiotics are like carpet-bombing an industrial district β you kill the invaders, but you also destroy the infrastructure that keeps the region functioning.
ΒΆ Mechanism
The microbiome operates through multiple integrated mechanisms:
Metabolic Production Cascade:
- Dietary fiber (indigestible polysaccharides) β bacterial fermentation β Short-chain fatty acids (Butyrate, propionate, acetate)
- Butyrate binds GPR109A and GPR43 on colonocytes β inhibits HDACs β promotes Treg differentiation via FOXP3 expression
- Butyrate also serves as primary energy source for colonocytes β maintains gut barrier integrity β reduces Intestinal permeability
- Propionate β transported to liver β suppresses cholesterol synthesis and gluconeogenesis
- Acetate β enters systemic circulation β affects appetite regulation via hypothalamic signaling
Vitamin Synthesis Pathways:
- Bifidobacteria and Lactobacillus species β synthesize B vitamins (riboflavin, folate, biotin, B12)
- Bacteroides and E. coli strains β produce vitamin K2 (Vitamin K2) β activates Osteocalcin and Matrix Gla-Protein
Bile Acid Metabolism:
- Primary Bile acids (conjugated) β bacterial bile salt hydrolases β deconjugation
- Secondary bile acids (deoxycholic acid, lithocholic acid) β bind TGR5 and FXR receptors β regulate glucose metabolism, energy expenditure, GLP-1 secretion
Immune Training Network:
- Bacterial MAMPs (microbe-associated molecular patterns) β TLR activation on dendritic cells and macrophages
- TLR4 recognizes bacterial LPS β NF-kB activation β IL-10 production in tolerogenic DCs
- Segmented filamentous bacteria β induce Th17 cells in GALT β IL-17 production β maintains mucosal barrier
- Akkermansia-muciniphila β secretes proteins that strengthen tight junctions β increases Occludin and ZO-1 expression
Neurotransmitter Production:
- Lactobacillus and Bifidobacterium β produce GABA via glutamate decarboxylase
- Enterococcus and Streptococcus β synthesize Serotonin precursors (95% of body's serotonin produced in gut)
- E. coli and Enterococcus β produce Dopamine and norepinephrine
- These metabolites β signal via Vagus nerve afferents and enterochromaffin cells β influence gut-brain axis
Pathogen Exclusion Mechanisms:
- Competitive exclusion for binding sites on intestinal epithelium
- Production of Bacteriocins (antimicrobial peptides targeting competing species)
- Lactobacillus species β produce lactic acid β lower luminal pH β inhibit pathogen growth
- Consumption of available nutrients β metabolic niche occupation
ΒΆ Clinical Significance
The microbiome is central to cPNI practice as a primary driver of the five metamodels, particularly metamodel 1 (stress axes) and metamodel 3 (chronic inflammation). Microbiome optimization represents a foundational intervention that influences all Selfish systems.
Patient Populations:
- Essential in all chronic inflammatory conditions: inflammatory bowel disease, rheumatoid arthritis, psoriasis, asthma
- Critical in metabolic dysfunction: Type 2 Diabetes, obesity, NAFLD, metabolic syndrome
- Neuropsychiatric presentations: Depression, Anxiety, Autism, ADHD, chronic fatigue
- Autoimmune diseases where immune tolerance has failed: Hashimoto's thyroiditis, Multiple Sclerosis, Type 1 diabetes
- Cancer patients (microbiome influences checkpoint inhibitor response)
Evolutionary Mismatch Context:
The Western microbiome shows dramatically reduced diversity compared to hunter-gatherer populations (50-70% fewer species). This represents a profound mismatch: our immune system evolved expecting continuous microbial exposure for training and regulation. The hygiene hypothesis and old friends mechanism explain how reduced microbial diversity β inadequate immune training β loss of immune tolerance β allergies and autoimmune diseases.
Clinical Thresholds and Biomarkers:
- Firmicutes/Bacteroidetes ratio: >3:1 associated with obesity, metabolic dysfunction
- Fecal Calprotectin: >50 ΞΌg/g indicates intestinal inflammation, microbiome disruption
- Zonulin (intestinal permeability marker): >50 ng/mL suggests leaky gut associated with dysbiosis
- Fecal SCFA levels: Butyrate <10 ΞΌmol/g indicates reduced fiber fermentation capacity
- Diversity indices (Shannon, Simpson): Lower values (
.5 Shannon index) correlate with disease across conditions
Intervention Strategy in cPNI:
- Prebiotic fiber intake: 30-40g/day from diverse plant sources β selective feeding of beneficial bacteria β SCFA production
- Fermented foods: Daily intake (kimchi, sauerkraut, kefir) β introduce live bacteria β enhance diversity
- Polyphenols: >500mg/day β selectively promote Akkermansia-muciniphila, Lactobacillus, Bifidobacteria
- Antibiotic stewardship: Avoid unnecessary courses β preserve diversity
- Circadian rhythm alignment: Eating within 8-10 hour window β bacterial oscillations influence metabolic health
- Stress management: Chronic stress β Cortisol β alters microbiome composition β dysbiosis β metaflammation
The microbiome exemplifies the selfish immune system concept: these organisms protect their ecological niche by training our immune system to tolerate them while attacking competitors. When we disrupt this balance, the immune system loses its primary regulatory input.
ΒΆ Key Facts
- Contains 100 trillion organisms, outnumbering human cells 1.3:1 by current estimates (previous 10:1 ratio revised)
- Harbors >1000 bacterial species, predominantly from phyla Firmicutes, Bacteroidetes, Actinobacteria, Proteobacteria
- Produces 95% of body's Serotonin via enterochromaffin cells in gut
- Generates vitamins K, B12, folate, biotin, riboflavin, thiamine that humans cannot synthesize
- Butyrate production ranges 10-40 ΞΌmol/g in healthy individuals, <5 ΞΌmol/g in IBD patients
- Approximately 70-80% of immune cells (IgA-producing plasma cells, Tregs) reside in gut-associated lymphoid tissue
- Diversity decreases ~25% between ages 20-70 in Western populations
- Vaginal delivery seeds infant microbiome with maternal Lactobacillus and Bifidobacterium; C-section infants show skin/environmental bacteria dominance
- Single antibiotic course can reduce diversity for 6-12 months; multiple courses β permanent species loss
- Low diversity (Shannon index .0) independently predicts all-cause mortality
- Microbiome composition shifts within 24 hours of dietary change but requires 3-6 months for stable reprogramming
- Hunter-gatherer microbiomes contain 30-40% more species than Western populations
ΒΆ Connections
- Short-chain fatty acids β primary metabolic products driving colonocyte health, immune regulation, and systemic metabolism
- Butyrate β key SCFA produced by fiber fermentation; fuels colonocytes, promotes Tregs, inhibits inflammation
- gut-brain axis β bidirectional communication via vagal afferents, neurotransmitter production, and immune signaling
- Vagus nerve β carries microbiome signals to brainstem, mediating mood and inflammatory responses
- dysbiosis β imbalanced microbiome state characterized by reduced diversity and pathogenic overgrowth
- gut barrier β microbiome maintains tight junction integrity; dysbiosis increases intestinal permeability
- Intestinal permeability β "leaky gut" driven by loss of beneficial bacteria and reduced butyrate production
- Zonulin β biomarker of intestinal permeability influenced by microbiome composition
- metaflammation β chronic low-grade inflammation fueled by dysbiotic microbiome and endotoxemia
- chronic low-grade inflammation β sustained by bacterial LPS translocation when barrier function fails
- LPS β bacterial endotoxin that activates TLR4, driving systemic inflammation when microbiome barrier is compromised
- immune training β continuous microbial exposure educates immune system from birth, establishing tolerance
- GALT β gut-associated lymphoid tissue where 70% of immune cells interact with microbiome
- Treg β regulatory T cells induced by butyrate and other microbial metabolites; prevent autoimmunity
- IgA β secretory antibody coating gut bacteria, maintaining homeostatic microbiome composition
- TLR4 β pattern recognition receptor recognizing bacterial LPS; central to microbiome-immune dialogue
- SCFA β collective term for butyrate, propionate, acetate produced by fiber fermentation
- Bile acids β metabolized by microbiome into secondary bile acids that regulate metabolism via TGR5/FXR
- Polyphenols β plant compounds selectively feeding beneficial bacteria like Akkermansia
- Akkermansia-muciniphila β keystone species strengthening gut barrier, improving metabolic health
- Bifidobacteria β beneficial genus producing B vitamins, enhancing barrier function, suppressing pathogens
- Lactobacillus β probiotic genus producing lactic acid, GABA, and immune-regulatory signals
- FOXP3 β transcription factor for Treg development, upregulated by butyrate via HDAC inhibition
- HDACs β histone deacetylases inhibited by butyrate, allowing Treg differentiation
- NF-kB β inflammatory transcription factor activated by dysbiotic LPS, suppressed by healthy microbiome
- IL-10 β anti-inflammatory cytokine produced by Tregs in response to beneficial bacteria
- Depression β linked to reduced microbial diversity, low butyrate, and altered tryptophan metabolism
- Autism β associated with distinct microbiome signatures and altered gut-brain signaling
- obesity β characterized by reduced diversity, elevated Firmicutes/Bacteroidetes ratio, low butyrate
- Type 2 Diabetes β dysbiosis contributes via endotoxemia, reduced SCFA, and impaired GLP-1 secretion
- inflammatory bowel disease β severe dysbiosis with loss of Faecalibacterium, overgrowth of Proteobacteria
- autoimmune disease β loss of microbial immune training leads to failed tolerance and self-attack
- Cancer β microbiome influences chemotherapy efficacy, checkpoint inhibitor response, and inflammation
- hygiene hypothesis β reduced microbial exposure in childhood impairs immune training, increases allergy/autoimmunity
- old friends mechanism β co-evolved microbes are necessary for immune system calibration
- diet β single most powerful modulator of microbiome composition, acting within hours
ΒΆ Module References
- Module 1